Company Overview and News

2
Linn Energy Planning On Splitting Into 2 Companies Soon

2018-06-11 seekingalpha
Roan Resources will hold the Merge/SCOOP/STACK assets and has been growing rapidly with production now 60% higher than in September 2017.
LINEQ LNGG LINE

20
Revisiting MLP Distribution Growth

2018-06-06 seekingalpha
It's a perennial favorite, with investors and industry insiders requesting it over and over again. We wanted to provide a simple number that could be referenced and compared. Something like the GDP growth rate, which on its face is a quick look at the economy, but in reality, is a simplified summary of a nuanced subject.
LINEQ ETP.PRC LGCYP LGCYO BBPPQ LNGG VNRR BBEP WPZ ETP VNR LGCY VNRAP VNRBP VNRCP BBEPQ EEP PAA BBEPP LINE

2
25th Anniversary Of Financial Shenanigans With Howard Schilit

2018-06-01 valuewalk
Financial Reporting & Analysis Edition – “25th Anniversary of Financial Shenanigans with Howard Schilit” from a recent CFA NY conference
LINEQ LNGG LINE

2
Linn Energy's (LNGG) CEO Mark Ellis on Q1 2018 Results - Earnings Call Transcript

2018-05-03 seekingalpha
Linn Energy IncA (OTCQB:LNGG) Q1 2018 Results Earnings Conference Call May 3, 2018 11:00 AM ET
LINEQ LNGG LINE

2
LINN Energy Reports First-Quarter 2018 Results

2018-05-03 globenewswire
HOUSTON, May 03, 2018 (GLOBE NEWSWIRE) -- LINN Energy, Inc. (OTCQB:LNGG) (“LINN” or the “Company”) announces financial and operating results for the first quarter 2018 and highlights the following:
LINEQ LNGG LINE

9
CEO Awarded $60 Million to Lead Linn Energy Firm Past Bankruptcy - Bloomberg

2018-04-19 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
LINEQ LNGG XOM LINE

3
BRIEF-Linn Energy Provides A Strategic Update On Separation

2018-04-18 reuters
* LINN ENERGY PROVIDES A STRATEGIC UPDATE ON SEPARATION, ANNOUNCES NEW LEADERSHIP AND SCHEDULES FIRST QUARTER 2018 EARNINGS CONFERENCE CALL
LINEQ LNGG LINE

2
LINN Energy Provides a Strategic Update on Separation, Announces New Leadership and Schedules First Quarter 2018 Earnings Conference Call

2018-04-18 globenewswire
HOUSTON, April 18, 2018 (GLOBE NEWSWIRE) -- LINN Energy, Inc. (OTC:LNGG) (“LINN” or the “Company”) provides a strategic update on the previously announced separation, announces new leadership and schedules its first quarter 2018 earnings conference call.
LINEQ LNGG LINE

174
[Press] Natural Gas Liquids (NGLs) Industry Global Market Size, Growth, Trends, Share and 2023 Forecasts Report

2018-04-10 oilvoice
Natural Gas Liquids (NGLs) Industry report offers a comprehensive insight into the development policies and plans in addition to manufacturing processes and cost structures. On the basis of product, this report displays the Cost Structure, Sales Revenue, Sales Volume, Gross Margin, market share and growth rate.
XOM LNGG CHKVP DVN BP RRL RDSB RDSA CHKDH CHKVZ SWTF CHKDG SU COP CHKDJ CHKDP SFY RYDAF CHK.PRD SU LINEQ CKRGZ RDS.B RDS.A SM SBOW RRS BP.A BP.B RGRLF CHKWZ RRC BP RGRYY CNQ CHK.WI CHK RYDBF STOHF BPAQF LINE STO

4
Valuing Mid-Con Energy Partners Based On PV-10 And EBITDA

2018-04-09 seekingalpha
Based on the PV-10 of its reserves and other mature asset sales, Mid-Con's value is estimated at $1.88 per common unit.
LINEQ LNGG LINE MCEP

7
Breitburn Energy Partners: Bankruptcy Proceedings Are Nearing The End

2018-03-21 seekingalpha
Second-lien bondholders will receive a strong recovery via ownership of Breitburn's legacy assets, while unsecured bondholders will receive a modest recovery.
LINEQ BBPPQ LNGG BBEP BBEPQ BBEPP LINE

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

13h - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

13h - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Silicon Investor Message Boards

This table lists all message boards related to LINE / Linn Energy, LLC on message board site Silicon Investor.

Media Industries: Newspapers, TV, Radio, Movies, Online American Airlines Group, Inc.
Gridline Communications Zillow -- An online real estate center
America On-Line (AOL) United Airlines
Priceline.com (PCLN)...another hot IPO ? Alaska Natural Gas Pipeline
Southwest Airlines (LUV)) Timberline Resources
CUSIP: 536020100